Fluorophore Localization Determines the Results of Biodistribution of Core-Shell Nanocarriers
Alicja Hinz,Marta Szczęch,Krzysztof Szczepanowicz,Monika Bzowska
DOI: https://doi.org/10.2147/IJN.S343266
IF: 7.033
2022-02-08
International Journal of Nanomedicine
Abstract:Alicja Hinz, 1 Marta Szczęch, 2 Krzysztof Szczepanowicz, 2 Monika Bzowska 1 1 Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland; 2 Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences, Kraków, Poland Correspondence: Monika Bzowska Department of Cell Biochemistry, Faculty of Biochemistry, Jagiellonian University in Kraków, Biophysics and Biotechnology, 7 Gronostajowa Street, Kraków, 30-387, Poland, Tel/Fax +48 12 664 63 88, Email Krzysztof Szczepanowicz Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences, Niezapominajek 8 Street, Kraków, 30-239, Poland, Tel/Fax +48 12 639 51 21, Email Introduction: Biodistribution of nanocarriers with a structure consisting of core and shell is most often analyzed using methods based on labeling subsequent compartments of nanocarriers. This approach may have serious limitations due to the instability of such complex systems under in vivo conditions. Methods: The core-shell polyelectrolyte nanocarriers were intravenously administered to healthy BALB/c mice with breast cancer. Next, biodistribution profiles and elimination routes were determined post mortem based on fluorescence measurements performed for isolated blood, tissue homogenates, collected urine, and feces. Results: Despite the surface PEGylation with PLL-g-PEG, multilayer polyelectrolyte nanocarriers undergo rapid degradation after intravenous administration. This process releases the shell components but not free Rhodamine B. Elements of polyelectrolyte shells are removed by hepatobiliary and renal clearance. Conclusion: Multilayer polyelectrolyte nanocarriers are prone to rapid degradation after intravenous administration. Fluorophore localization determines the obtained results of biodistribution and elimination routes of core-shell nanomaterials. Therefore, precise and reliable analysis of in vivo stability and biodistribution of nanomaterials composed of several compartments requires nanomaterials labeled within each compartment. Keywords: in vivo studies, fluorescently labeled nanomaterials, stealth polymers, pharmacokinetics, routes of elimination, nanocarriers stability and degradation Evaluation of nanomaterial pharmacokinetics, biodistribution, and clearance is essential in preclinical studies of all nanomedicines, regardless of their route of administration and proposed use. Determining the half-life of nanoparticles in the serum, the degree of their accumulation in organs, and elimination routes allows predicting tissues exposed to the potentially toxic nanocarriers and verify nanoparticles retention in the diseased tissues. Moreover, the analysis of pharmacokinetics, especially in serum, provides indirect information on the stability of nanoparticles since the short half-life in serum often results from premature nanomaterial breakdown in the bloodstream immediately after administration. 1 The pharmacokinetics and biodistribution of nanocarriers are determined primarily by their chemical structure, physical properties, the administration route, and the unique biological properties of tissues that, after administration, have direct contact with nanomaterials. 2 For example, Enhance Permeability and Retention phenomenon (EPR) allows the accumulation of nanomaterials in these tumors characterized by blood vessels with increased permeability and reduced lymphatic drainage. 3 Analysis of the nanomaterial retention in tissues or body fluids often involves measurements of the active agent concentration transported by the nanocarriers (eg anti-cancer drug). 4 Another approach requires labeling nanomaterials with various isotopes, fluorophores, or metals. Pharmacokinetics and biodistribution are then determined using radiation or fluorescence measurements, magnetic resonance imaging, or computed tomography. To further complicate, the signal may be detected either intravitally or postmortem. 5 In the case of intravital imaging, anesthesia is required, which may influence the results of pharmacokinetic analysis (anesthesia lowers, eg the cardiac index). 6 The molecules employed for nanomaterial labeling are attached within the nanoparticle by covalent bonds, electrostatic interactions, or immobilized in the nanomaterial compartment to which they have increased affinity (eg hydrophilic molecules inside liposomes). Additionally, some nanocarriers are made of more than one compartment (eg core-shell nanoparticles); thus, the label may be located in a different part of the nanoparticle. Nanomaterials of this type can be made of organic and inorganic components, -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology